Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 2, 2007, Pages 132-143

  McClure, David L ^a,d   Valuck, Robert J ^b   Glanz, Morton ^c   Hokanson, John E ^b  

^a CLINICAL RESEARCH UNIT   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

Adverse events; HMG CoA reductase inhibitors; Meta analysis; Myopahty; Rhabdomyolysis; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MUSCLE DISEASE; MYALGIA; MYOSITIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; MYOSITIS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RHABDOMYOLYSIS; RISK ASSESSMENT;

EID: 33847243361     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1341     Document Type: Review

References (145)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). LANCET 1994; 344: 1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349-1357.
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615-1622.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. LANCET 2002; 360(9326): 7-22.
7. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. LANCET 2003; 361(9364): 1149-1158.
8. Colhoun HM, Betteridge JD, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. LANCET 2004; 364: 685-696.
9. Baigent C, Landray M, Leaper C, et al. First United Kingdom heart and renal protection (UK-HARP-I) study: Biochemical efficacy and safety of Simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2006; 45(3): 473-484.
10. Bak AA, Huizer J, Leijten PA, et al. Diet and pravastatin in moderate hypercholesterolaemia: A randomized trial in 215 middle-aged men free from cardiovascular disease. J Intern Med 1998; 244(5): 371-378.
11. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-133.
12. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia A prospective, randomized, double-blind trial. Circulation 2003; 107(19): 2409-2415.
13. Behounek BD, McGovern ME, Kassler-Taub KB, et al. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/ liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72(14): 1031-1037.
14. Behounek BD, McGovern ME, Kassler-Taub KB, et al. A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multinational Study Group for Diabetes. Clin Cardiol 1994; 17(10): 558-562.
15. Beigel Y, Brook G, Eisenberg S, et al. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience. Isr J Med Sci 1993; 29(5): 272-277.
16. Betteridge DJ, Bhatnager D, Bing RF, et al. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ 1992; 304: 1335-1338.
17. Betteridge DJ. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. International Cerivastatin Study Group. Int J Clin Pract 1999; 53(4): 243-250.
18. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993; 119(10): 969-976.
19. Bradford RN, Shear CL, Chermos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results; two year efficacy and safety follow-up. Am J Cardiol 1994; 74: 667-673.
20. Celis H, Lijnen P, Fagard R, et al. Efficacy and safety of pravastatin in hypertensive hypercholesterolaemic patients on antihypertensive drug therapy. J Hum Hypertens 1994; 8: 525-530.
21. Chan DC, Watts GF, Mori TA, et al. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 2002; 32: 429-436.
22. Chan P, Lee CB, Lin TS, et al. The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. Am J Hypertens 1995; 8: 1099-1104.
23. Chan P, Tomlinson B, Lee CB, et al. Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. Hypertension 1996; 28: 647-651.
24. Chan P, Tomlinson B, Lee CB, et al. Effectiveness and safety of low-dose pravastatin and squalene, alone and in combination, in elderly patients with hypercholesterolemia. J Clin Pharmacol 1996; 36: 422-427.
25. Chan P, Huang TY, Tomlinson B, et al. Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia. J Clin Pharmacol 1997; 37: 496-501.
26. Cilla DD, Jr., Whitfield LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996; 60: 687-695.
27. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 1294-1304.
28. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79: 1475-1481.
29. Davidson MH, Testolin LM, Maki KC, et al. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997; 157: 1186-1192.
30. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001; 24: 467-474.
31. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-2134.
32. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268-275.
33. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994; 73: 339-345.
34. Derosa G, Mugellini A, Ciccarelli L, et al. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003; 25: 1107-1122.
35. Diabetes Atorvastatin Lipid Intervention Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: A double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001; 24: 1335-1341.
36. Dobs AS, Schrott H, Davidson MH, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000; 49: 1234-1238.
37. Duffy SJ, O'Brien RC, New G, et al. Effect of anti-oxidant treatment and cholesterol lowering on resting arterial tone, metabolic vasodilation and endothelial function in the human forearm: A randomized, placebo-controlled study. Clin Exp Pharmacol Physiol 2001; 28: 409-418.
38. Dujovne CA, Bays H, Davidson MH, et al. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: Results of a multicenter dose-ranging study. J Clin Pharmacol 2001; 41: 70-78.
39. Farrer M, Winocour PH, Evans K, et al. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994; 23: 111-119.
40. Ferrari P, Weidmann P, Riesen WF, et al. Pravastatin in the treatment of primary hypercholesterolemia: A Swiss multicenter study. Schweiz Med Wochenschr 1993; 123: 1736-1741.
41. Fang RL, Ward HJ. The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia. Am J Med 1997; 102: 387-391.
42. Frederiksen SM, Larsen ML, Oxenboll IB, et al. Treatment of primary hypercholesterolemia with pravastatin. A placebo-controlled trial. Ugeskrift for Laeger 1993; 155: 2794-2799.
43. Furberg CD, Adams HP, Jr., Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679-1687.
44. Giannini SD, De Goes JM, Dereviacki BE, et al. Simvastatin in the treatment of elderly patients with primary hypercholesterolemia. Current Thera Res 1994; 55: 161-171.
45. Glasser SP, DiBianco R, Effron BA, et al. The efficacy and safety of Pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160mg/dl. Am J Cardiol 1996; 77: 83-85.
46. Guillen MA, Kornhauser C, Samaniego V, et al. Once-daily pravastatin compared with dietary advice in patients with borderline and moderate primary hypercholesterolemia. Cur Ther Res 1995; 56: 305-316.
47. Harris KP, Wheeler DC, Chong CC, et al. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 2002; 61: 1469-1474.
48. Hartog FR, van Kalmthout PM, van Loenhout TT, et al. Pravastatin in acute ischaemic syndromes: Results of a randomised placebo-controlled trial. Int J Clin Proc 2001; 55: 300-304.
49. Hommel E, Andersen P, Gall MA, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992; 35: 447-451.
50. Huhle G, Abletshauser C, Mayer N, et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999; 95: 229-234.
51. Hunninghake DB, Knapp RH, Schonfeld G, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis 1990; 85: 81-89.
52. Hunninghake DB, Mellies MJ, Goldberg AC, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. Atherosclerosis 1990; 85: 219-227.
53. Hunninghake D, Insull W, Jr., Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158: 407-416.
54. Insull W, Jr., Black D, Dujovne C, et al. Efficacy and safety of once-daily vs. twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994; 154: 2449-2455.
55. Isaacsohn J, Insull W, Stein E, et al. Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Clin Cardiol 2001; 24: IV1-IV9.
56. Isaacsohn J, Hunninghake D, Schrott H, et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol 2003; 26: 18-24.
57. Jacobson TA, Chin MM, Fromell GJ, et al. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994; 74: 149-154.
58. Jacobson TA, Chin MM, Curry CL, et al. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. Arch Intern Med 1995; 155: 1900-1906.
59. Jacotot B, Banga JD, Pfister P, et al. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. Br J Clin Pharmacol 1994; 38: 257-263.
60. Jones PH, Farmer JA, Cressman MD, et al. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 1991; 14: 146-151.
61. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-2540.
62. Keech A, Collins H, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: Assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-269.
63. Knopp RH, Frohlich J, Jokubaitis LA, et al. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med 1994; 96: 69S-78S.
64. Krempf M, Berthezene F, Wemeau JL, et al. Efficacy of low-dose pravastatin in patients with mild hyperlipidemia associated with type II diabetes mellitus. Diabetes Metab 1997; 23: 131-136.
65. Kuhn P, Darioli R, Bovet P, et al. Dose-dependent lipid-lowering effects of simvastatin (MK-733) in the elderly. Cur Thera Res 1989; 46: 381-389.
66. Lepre F, Nestel I, Clifton P, et al. Low-dose simvastatin in the treatment of mild to moderate hypercholesterolaemia. Clin Drug Invest 1997; 13: 237-241.
67. Lindholm LH, Ekbom T, Dash C, et al. Changes in cardiovascular risk factors by combined pharmacological and non-pharmacological strategies: The main results of the CELL Study. J Intern Med 1996; 240: 13-22.
68. Lintott CJ, Scott RS, Bremer JM, et al. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Am J Cardiol 1995; 76: 97A-101A.
69. Luscher F. other Encore Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease - The ENCORE I study (Evaluation of nifedipine and cerivastatin on recovery of coronary endothelial function). Circulation 2003; 107: 422-428.
70. Lye M, Valacio R, Reckless JP, et al. Elderly patients with hypercholesterolaemia: A double-blind study of the efficacy, safety and tolerability of fluvastatin. Coron Artery Dis 1998; 9: 583-590.
71. Marz W, Scharnagl H, Abletshauser C, et al. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 2001; 103: 1942-1948.
72. McCrea JB, Fruncillo RJ, Holland SD, et al. Lovastatin does not affect oral glucose tolerance in hypercholesterolemic patients. J Clin Pharmacol 1993; 33: 581-585.
73. McDowell IF, Smye M. Trinick T, et al. Simvastatin in severe hypercholesterolaemia: A placebo controlled trial. Br J Clin Pharmacol 1991; 31: 340-343.
74. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993; 13: 439-444.
75. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Eur Heart J 2003; 24: 717-728.
76. Meyers DG, Bays HE, Weiner BH, et al. Short-term efficacy and safety of pravastatin in hypercholesterolemic women. J Women Health 1995; 4: 357-365.
77. Mol MJ, Erkelens DW, Leuven JA, et al. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. LANCET 1986; 2: 936-939.
78. Morgan T, Anderson A, McDonald P, et al. Simvastatin in the treatment of hypercholesterolaemia in patients with essential hypertension. J Hypertens Suppl 1990; 8: S25-S30.
79. Muscari A, Bastagli L, Poggiopollini G, et al. Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men. Cardiovas Drug Ther 2001; 15: 453-458.
80. Nakamura H, Ohashi Y, Maruhama Y, et al. Efficacy of atorvastatin in primary hypercholesterolemia. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Am J Cardiol 1997; 79: 1248-1252.
81. Nakamura Y, Yamaoka O, Uchida K, et al. Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: Results of SHIPS (SHIga Pravastatin Study). Cardiovas Drug Ther 1996; 10: 475-483.
82. Nakaya N, Homma Y, Tamachi H, et al. The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers. Atherosclerosis 1986; 61: 125-128.
83. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-682.
84. Olsson AG, Pears J, McKellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504-508.
85. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian simvastatin survival study. Arch Intern Med 1996; 156: 2085.
86. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105: 2341.
87. Pitt B, Mancini GB, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995; 26: 1133-1139.
88. Plotkin D, Miller S, Nakajima S, et al. Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, does not affect luteal function in premenopausal women. J Clin Endocrinol Metab 2002; 87: 3155-3161.
89. Pravastatin Multicenter Study GroupII Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II. Arch Intern Med 1993; 153: 1321-1329.
90. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999; 144: 263-270.
91. Ritter JM, Sever P, Brassfield T. Pravastatin once daily in hypercholesterolaemia: A U.K. study. J Clin Pharm Ther 1993; 18: 421-426.
92. Roth T, Richardson GR, Sullivan JP, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992; 15: 426-432.
93. Rubenfire M, Maciejko JJ, Blevins RD, et al. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. Arch Intern Med 1991; 151: 2234-2240.
94. Rustemeijer C, Schouten JA, Janssens EN, et al. Pravastatin in diabetes-associated hypercholesterolemia. Acta Diabetol 1997; 34: 294-300.
95. Sabia H, Prasad P, Smith HT, et al. Safety, tolerability, and pharmarokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J Cardiovasc Pharmacol 2001; 37: 502-511.
96. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-1764.
97. Saltissi D, Morgan C, Rigby RJ, et al. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J of Kidney Dis 2002; 39: 283-290.
98. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) pilot study. J Am Geriatr Soc 1997; 45: 8-14.
99. Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med 1994; 96: 509-515.
100. Sartor G, Katzman P, Eizyk E, et al. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. Int J Clin Pharmacol and Ther 1995; 33: 3-6.
101. Saxenhofer H, Weidmann P, Riesen WF, et al. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II. Eur J Clin Pharmacol 1990; 39: 101-105.
102. Schrott HG, Knapp H, Davila M, et al. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: A randomized, placebo-controlled study. Am Heart J 2000; 140: 249-252.
103. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-1718.
104. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999; 20: 58-69.
105. Serruys PWJC, De Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 287: 3215-3222.
106. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. LANCET 2002; 360: 1623-1630.
107. Sheu WH, Jeng CY, Lee WJ, et al. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia. Metabol 2001; 50: 355-359.
108. Simons LA, Nestel PJ, Calvert GD, et al. Effects of MK-733 on plasma lipid and lipoprotein levels in subjects with hypercholesterolaemia. Med J Aust 1987; 147: 65-68.
109. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesteralemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52: 346-350.
110. Simoons ML, Saelman JPM, Deckers JW, et al. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). LANCET 1994; 344: 633-638.
111. Smit JWA, Van Erpecum KJ, Renooij W, et al. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 1995; 21: 1523-1529.
112. Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients [comment]. Ann Intern Med 1994; 120: 37-43.
113. Stein E, Sprecher D, Allenby KS, et al. Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor. Effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovas Pharmacol Ther 1997; 2: 7-16.
114. Tanaka A, Yamada N, Saito Y, et al. A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. Clin Chim Acta 2001; 312: 41-47.
115. Thomas ME, Harris KP, Ramaswamy C, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993; 44: 1124-1129.
116. Tobert JA, Hitzenberger G, Kukovetz WR, et al. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis 1982; 41: 61-65.
117. Tobert JA, Bell GD, Birtwell J, et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J Clin Invest 1982; 69: 913-919.
118. Tuomilehto J, Guimaraes AC, Kettner H, et al. Dose-response of simvastatin in primary hypercholesterolemia. J Cardiovas Pharmacol 1994; 24: 941-949.
119. Wang KY. C.T. Ting CT, A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. Jap Heart J 2001; 42: 725-738.
120. Watts GF, Chan DC, Barrett PHR, et al. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Intern J Obes 2003; 27: 862-865.
121. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 1994; 331: 1331-1337.
122. Wiklund O, Angelin B, Fager G, et al. Treatment of familial hypercholesterolaemia a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med 1990; 228: 241-247.
123. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13-20.
124. Winkler K, Abletshauser C, Hoffmann MM, et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: Baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 2002; S7: 5485-5490.
125. Pasternak RC, Smith SC, Jr., Bairey-Merz SC, et al. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024-1028.
126. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-1690.
127. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 46(7): 539-540.
128. Sutton AJ, Cooper NJ, Lambert PC, et al. Meta-analysis of rare and adverse event data. Expert Rev Pharmacoecon Outcome Res 2002; 2(4): 367-379.
129. Egger MSmith GD, Altman DG. (eds). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd ed. BMJ Publishing Group: London, 2001.
130. Whitehead A. Meta-Analysis of Controlled Clinical Trials. Wiley: West Sussex England, 2002.
131. Clarke M, Oxman AD. (eds). Cochrane Reviewers Handbook 4. 1. 5 [updated April 2002]; In: The Cochrane Library, Issue 2. 2002; Oxford, Update Software. Updated quarterly.
132. Valuck RJ, Byrns PJ, Fulda TR, Vander Zanden J, Parker S. Methodology for assessing drug-drug interaction: Evidence in the peer-reviewed medical literature. Cur Ther Res 2000; 68(8): 553-568.
133. Clarke M, Oxman AD. (eds). Appendix B: Medline search strategies for optimal sensitivity in identifying randomised clinical trials. Cochrane Reviewers Handbook 4. 1. 5 [updated April 2002]; Section 11a. 15. In: The Cochrane Library, Issue 2. 2002; Oxford, Update Software. Updated quarterly.
134. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 29: 743-759.
135. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
136. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd ed. Egger MSmith GD, Altman DG. (eds). BMJ Publishing Group: London, 2001; 285-312.
137. Whitehead A. Dealing with non-standard data sets In: Meta-Analysis of Controlled Clinical Trials. Wiley: West Sussex England, 2002; 215-220.
138. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003; 326: 1423-1430.
139. Jones PH, Davidson MH, Stein EA. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 93(2): 152-160.
140. The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Oxford: England, 2002.
141. StataCorp. Statistical Software: Release 8.0. College Station. Stata Corporation: TX. 2003.
142. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28(1): 26-35.
143. Report of the National Lipid Association's Statin Safety Task Force McKenney J, (ed.). Am J Cardiol 2006; 97 8S S1-S98.
144. de Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: A meta-analysis. Pharmacotherapy 2004; 24(5): 584-591.
145. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Report of the National Lipid Association's Statin Safety Task Force. Am J Cardiol 2006; 97(8S): S77-S81.